

February 10, 2026

The Honorable William Sutton, Chairperson
 House Committee on Insurance
 300 SW 10th Avenue, Room 218-N
 Topeka, Kansas 66612

Dear Representative Sutton:

SUBJECT: Fiscal Note for HB 2526 by House Committee on Insurance

In accordance with KSA 75-3715a, the following fiscal note concerning HB 2526 is respectfully submitted to your committee.

HB 2526 would prohibit a health benefit plan that provides coverage for advanced metastatic breast cancer and associated conditions from requiring an enrolled individual to fail to successfully respond to a different drug or to have a history of failure with a different drug before providing prescription drug coverage. The bill would only apply to a drug that is consistent with best practices for treatment of metastatic cancer; supported by peer-reviewed, evidence-based literature; and is approved by the U.S. Food and Drug Administration.

Estimated State Fiscal Effect			
	FY 2026	FY 2027	FY 2028
Expenditures			
State General Fund	--	--	--
Fee Fund(s)	--	\$113,111	\$122,726
Federal Fund	--	--	--
Total Expenditures	--	\$113,111	\$122,726
Revenues			
State General Fund	--	--	--
Fee Fund(s)	--	--	--
Federal Fund	--	--	--
Total Revenues	--	--	--
FTE Positions	--	--	--

The Division of State Employee Health Benefits Program in the Department of Administration indicates enactment of the bill would require \$113,111 in FY 2027 and \$122,726 in FY 2028 from the Health Benefits Administration Clearing Fund to provide the additional prescription drug coverage. Revenue in this fund comes from premiums collected for the State Employee Health Benefits Plan. The FY 2028 amount assumes an 8.5 percent increase, calculated by plan year, in the cost of providing the prescription drug coverage as compared to the FY 2027 amount.

The Department of Health and Environment indicates enactment of the bill could increase costs to the Medicaid program if the program is required to remove a step therapy protocol that aligns with national guidelines. The Department notes it does not currently manage any oncology agents with step therapy that are out of line with national recognized guidelines. The Department states a precise fiscal effect cannot be estimated.

The Department of Insurance indicates enactment of the bill would not have a fiscal effect on the agency. Any fiscal effect associated with HB 2256 is not reflected in *The FY 2027 Governor's Budget Report*.

The Kansas Association of School Boards indicates enactment of the bill could result in an increase in health insurance premium costs for school districts providing employee health insurance but anticipates any increase would be minimal. The Kansas Association of Counties indicates enactment of the bill could affect group or self-insured health insurance costs for counties, but that a fiscal effect cannot be estimated. The League of Kansas Municipalities states enactment of the bill would not have a fiscal effect on cities.

Sincerely,

A handwritten signature in black ink, appearing to read "Adam C. Proffitt", followed by a stylized flourish or symbol.

Adam C. Proffitt
Director of the Budget

cc: Samir Arif, Department of Administration
Kyle Strathman, Department of Insurance
Amy Penrod, Department of Health & Environment